An Orally Bioavailable Oxime Ether Capsid Binder with Potent Activity against Human Rhinovirus
Journal of Medicinal Chemistry2003Vol. 46(15), pp. 3181–3184
Citations Over TimeTop 25% of 2003 papers
Keith G. Watson, Renee N. Brown, Rachel Cameron, David K. Chalmers, Stephanie Hamilton, Betty Jin, Guy Y. Krippner, Angela Luttick, Darryl B. McConnell, Phillip A. Reece, Jane Ryan, Pauline C. Stanislawski, Simon P. Tucker, Wen‐Yang Wu, Dale L. Barnard, Robert W. Sidwell
Abstract
A series of capsid-binding compounds was screened against human rhinovirus (HRV) using a CPE based assay. The ethyl oxime ether 14 was found to have outstanding anti-HRV activity (median IC(50) 4.75 ng/mL), and unlike the equivalent ethyl ester compound 3 (Pirodavir), it has good oral bioavailability, making it a promising development candidate. Compound 14 illustrates that an oxime ether group can act as a metabolically stable bioisostere for an ester functionality.
Related Papers
- → Duration of Rhinovirus Shedding in the Upper Respiratory Tract in the First Year of Life(2014)84 cited
- → Clinical effects of rhinovirus infections(2008)100 cited
- → Impact of Capsid Conformation and Rep-Capsid Interactions on Adeno-Associated Virus Type 2 Genome Packaging(2005)72 cited
- → Survival of rhinoviruses on human fingers(2014)38 cited
- Detection and analysis of rhinovirus in acute upper respiratory tract infections in Shenzhen area from 2011 to 2012(2013)